Clinical Trial Update: BV After Allogeneic Hematopoietic Stem Cell Transplantation [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating Brentuximab vedotin after allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma; the current status is UNKNOWN.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• Adcetris (Brentuximab vedotin)

Snippet

Sponsor: University Hospital, Caen | Conditions: Hodgkin Lymphoma | Phase 2 | Status: UNKNOWN